Clinical Trials Logo
  1. Home
  2. Non-squamous NSCLC
  3. NCT05261438
  4. Details
NCT05261438 Clinical Trial

Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Non-squamous NSCLC Clinical Trial

Official title:
Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05261438
Other study ID # ATRRACT
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 1, 2019
Est. completion date September 15, 2021

Study information
Verified date September 2019
Source Hunan Province Tumor Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.

Description:

This study aimed to explore the efficacy of Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Non-squamous NSCLC.

Recruitment information / eligibility
Status Completed
Enrollment 70
Est. completion date September 15, 2021
Est. primary completion date May 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 18,Advanced Metastatic Non-squamous NSCLC Treatment Plan is atezolizumab-bevacizumab-carboplatin-paclitaxel Exclusion Criteria: Patients with contraindication of chemotherapy Pregnant or breast feeding women

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
China Hunan Cancer Hospital Changsha Hunan

Sponsors (1)
Lead Sponsor Collaborator
Hunan Province Tumor Hospital

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary OS overall survival September 2019- september 2021
Primary PFS progression-free survival September 2019- september 2021
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04413201 - AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC Phase 4
Active, not recruiting NCT04447118 - Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy Phase 3
Recruiting NCT03755869 - Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020） Phase 4
Withdrawn NCT04466917 - A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer Phase 3
Not yet recruiting NCT05782426 - Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC Phase 2
Recruiting NCT05751187 - Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients Phase 2
Terminated NCT02454842 - Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients Phase 2
Not yet recruiting NCT06206850 - Neo-Bio-ADAURA: A Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib Phase 2